RxDoctor Payments Data

Amy Gorczynski, MD

Internal Medicine · Whitesboro, NYNPI 1225022437

Payments from drug & device makers

$10,398in general payments, 2019–2025

Across 664 payments — averaging $15.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$851
  • Lilly USA, LLC$768
  • AstraZeneca$533
  • Amgen$428
  • Novo Nordisk$412
  • plus $5K from 40 others

What the payments were for

  • Food & beverage$10,32399%
  • Education$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,398 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$42,425
Medicare patients
194
Services billed
588

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$139,404
EliquisApixaban90$123,172
XareltoRivaroxaban64$90,477
TrulicityDulaglutide28$51,248
JardianceEmpagliflozin33$46,487
JanuviaSitagliptin Phosphate38$41,384
CreonLipase/Protease/Amylase12$34,464
MounjaroTirzepatide22$30,236
UbrelvyUbrogepant13$28,092
EntrestoSacubitril/Valsartan17$24,471
LinzessLinaclotide17$18,764
VraylarCariprazine Hcl11$14,961
OxycontinOxycodone Hcl18$14,124
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$10,694
Metoprolol Succinate259$7,962

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$412$139,40482 claims
PfizerEliquis, Paxlovid$851$127,303103 claims
AbbVieCreon, Ubrelvy, Linzess, Vraylar$2,253$96,28053 claims
Johnson & JohnsonXarelto$114$90,47764 claims
Lilly USA, LLCTrulicity, Mounjaro$768$81,48350 claims
Boehringer IngelheimJardiance$47$46,48733 claims
MerckJanuvia$228$41,38438 claims
NovartisEntresto$244$24,47117 claims
AstraZenecaSymbicort$533$5,54517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Whitesboro

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →